Stephen Gately

Stephen Gately is the President and Chief Executive Officer of Translational Drug Development, LLC (TD2), a company specializing in comprehensive preclinical drug development and clinical trial services, particularly in oncology.

Professional Background

• Education: Dr. Gately earned his PhD from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital.
• Previous Roles:
  • Consultant: Worked with Takeda Pharmaceuticals North America, focusing on integrating research and regulatory data for commercial planning.
  • Executive Director: Led Translational Medicine at NeoPharm, overseeing research design and implementation for product positioning.
  • Research Assistant Professor: At Northwestern University, he developed inhibitors of angiogenesis and consulted on clinical trial designs for antiangiogenic compounds at Searle/Monsanto (now Pfizer) .123

Current Role at TD2

Since becoming CEO, Gately has been instrumental in expanding TD2's services, including a recent initiative to establish a subsidiary in the UK to enhance their oncology ecosystem. His leadership is characterized by a commitment to revolutionizing oncology research through integrated approaches that combine preclinical services with robust regulatory support .25

LinkedIn Profile

For more details about his professional journey, you can view his LinkedIn profile here .4